1Delgado PL, Michaels T. Reboxetine: a review of efficacy and tolerability. Drugs of Today, 1999, 35(9): 725
2Dostert P, Benedelti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol, 1997, 7(suppl 1): 23
3Edwards DM, Pellizzoni C, Breuel HP, et al. Pharmacokinetics of reboxeetine in healthy volunteer: Single oral doses, linearity and plasma protein. Biopharm Drug Dispos, 1995, 16(6): 443
4Strolin Benedetti M, Frigerio E, Tocchetti P, et al. Steroselective and species-dependent kinetics of reboxetine in mouse and rat. Chirality, 1995, 7(4): 285
5Poggesi I, Pellizzoni C, Fleishaker JC. Pharmacalkinetics of reboxetine in elderely patients with depressive disorders. Int J Clin Pharmacal Ther, 2000, 38(5): 254
6Coulomb F, Ducret F, Laneury JP, et al. Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency. J Clin Pharmacol, 2000, 40(5): 482
7Wienkers LC, Allievi C, Hauer MJ, et al. Cytochlome P450-medieated metabolism of the individual enantiomers of the antidepressant agent reboxetine by human liver microsomes. Drug Metabo Dispos, 1999, 27(11): 1334
8Von Moltke LL, Greenblatt DJ, Schimder J, et al. Metabolism of drugs by cytochrome P450 3A isoforms. Clin Pharmacokinet,1995, 29(suppl 1): 33
9Cocciana G, Battalia R, Pevarello P, et al. Comparison of the disposition and of the metabolic patten of Reboxetine, a new antidepressant, in dog, monkey and man. Eur J Drug Metab Pharmacokinet, 1991, 16(3): 231
10Rogoz Z, Wrobel A, Krasicka-Domka M, et al. Pharmacological profile of reboxetine, a representative of new class of antidepressant drugs, selective noradrenaline reuptake inhibitor (NARI), given acutely. Pol J Pharmacol, 1999, 51(5): 399
